Standard BioTools Inc. (LAB)
USD 1.99
(-10.18%)
USD 1.99
(-10.18%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 50.45 Million USD | 36.16% |
| 2022 | 37.05 Million USD | -46.59% |
| 2021 | 69.37 Million USD | -16.75% |
| 2020 | 83.32 Million USD | 29.63% |
| 2019 | 64.27 Million USD | 4.27% |
| 2018 | 61.64 Million USD | 18.6% |
| 2017 | 51.98 Million USD | -11.05% |
| 2016 | 58.43 Million USD | -14.17% |
| 2015 | 68.08 Million USD | -7.51% |
| 2014 | 73.6 Million USD | 44.04% |
| 2013 | 51.1 Million USD | 38.08% |
| 2012 | 37 Million USD | 24.72% |
| 2011 | 29.67 Million USD | 35.01% |
| 2010 | 21.97 Million USD | 57.83% |
| 2009 | 13.92 Million USD | 99.43% |
| 2008 | 6.98 Million USD | 85.67% |
| 2007 | 3.76 Million USD | 3.75% |
| 2006 | 3.62 Million USD | 0.0% |
| 2001 | 77.26 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 23.26 Million USD | 56.03% |
| 2024 Q1 | 24.18 Million USD | 81.09% |
| 2024 Q2 | 14.9 Million USD | -38.37% |
| 2023 Q2 | 13.6 Million USD | 12.19% |
| 2023 Q1 | 12.12 Million USD | 8.57% |
| 2023 FY | 50.45 Million USD | 36.16% |
| 2023 Q4 | 13.35 Million USD | 19.75% |
| 2023 Q3 | 11.15 Million USD | -18.0% |
| 2022 Q4 | 11.16 Million USD | 21.12% |
| 2022 Q2 | 4.42 Million USD | -63.82% |
| 2022 FY | 37.05 Million USD | -46.59% |
| 2022 Q3 | 9.22 Million USD | 108.27% |
| 2022 Q1 | 12.23 Million USD | -39.55% |
| 2021 FY | 69.37 Million USD | -16.75% |
| 2021 Q1 | 19.04 Million USD | -27.37% |
| 2021 Q2 | 16.42 Million USD | -13.76% |
| 2021 Q3 | 13.66 Million USD | -16.76% |
| 2021 Q4 | 20.24 Million USD | 48.09% |
| 2020 Q4 | 26.21 Million USD | 3.55% |
| 2020 Q1 | 16.45 Million USD | -8.03% |
| 2020 FY | 83.32 Million USD | 29.63% |
| 2020 Q2 | 15.33 Million USD | -6.77% |
| 2020 Q3 | 25.31 Million USD | 65.07% |
| 2019 Q2 | 15.36 Million USD | -9.58% |
| 2019 FY | 64.27 Million USD | 4.27% |
| 2019 Q1 | 16.99 Million USD | -9.68% |
| 2019 Q3 | 14.03 Million USD | -8.62% |
| 2019 Q4 | 17.88 Million USD | 27.43% |
| 2018 Q1 | 13.42 Million USD | -6.01% |
| 2018 FY | 61.64 Million USD | 18.6% |
| 2018 Q2 | 13.58 Million USD | 1.19% |
| 2018 Q3 | 15.82 Million USD | 16.44% |
| 2018 Q4 | 18.81 Million USD | 18.89% |
| 2017 FY | 51.98 Million USD | -11.05% |
| 2017 Q4 | 14.28 Million USD | 17.27% |
| 2017 Q3 | 12.18 Million USD | 1.96% |
| 2017 Q2 | 11.94 Million USD | -11.91% |
| 2017 Q1 | 13.56 Million USD | -2.03% |
| 2016 FY | 58.43 Million USD | -14.17% |
| 2016 Q1 | 17.01 Million USD | -6.15% |
| 2016 Q2 | 15.68 Million USD | -7.86% |
| 2016 Q3 | 11.89 Million USD | -24.16% |
| 2016 Q4 | 13.84 Million USD | 16.42% |
| 2015 Q4 | 18.13 Million USD | 5.34% |
| 2015 Q1 | 16.08 Million USD | -22.38% |
| 2015 Q2 | 16.65 Million USD | 3.54% |
| 2015 Q3 | 17.21 Million USD | 3.36% |
| 2015 FY | 68.08 Million USD | -7.51% |
| 2014 Q4 | 20.72 Million USD | 13.76% |
| 2014 FY | 73.6 Million USD | 44.04% |
| 2014 Q3 | 18.21 Million USD | 3.18% |
| 2014 Q2 | 17.65 Million USD | 3.71% |
| 2014 Q1 | 17.02 Million USD | 12.92% |
| 2013 FY | 51.1 Million USD | 38.08% |
| 2013 Q4 | 15.07 Million USD | 14.63% |
| 2013 Q3 | 13.14 Million USD | 4.32% |
| 2013 Q2 | 12.6 Million USD | 22.65% |
| 2013 Q1 | 10.27 Million USD | -9.25% |
| 2012 Q4 | 11.32 Million USD | 22.24% |
| 2012 Q2 | 9.02 Million USD | 21.94% |
| 2012 Q3 | 9.26 Million USD | 2.68% |
| 2012 Q1 | 7.39 Million USD | -17.68% |
| 2012 FY | 37 Million USD | 24.72% |
| 2011 FY | 29.67 Million USD | 35.01% |
| 2011 Q3 | 7.29 Million USD | -4.2% |
| 2011 Q1 | 5.78 Million USD | -14.6% |
| 2011 Q4 | 8.98 Million USD | 23.28% |
| 2011 Q2 | 7.61 Million USD | 31.59% |
| 2010 Q4 | 6.77 Million USD | 12.66% |
| 2010 Q3 | 6.01 Million USD | 17.35% |
| 2010 Q2 | 5.12 Million USD | 25.84% |
| 2010 Q1 | 4.07 Million USD | -10.35% |
| 2010 FY | 21.97 Million USD | 57.83% |
| 2009 Q4 | 4.54 Million USD | 0.0% |
| 2009 FY | 13.92 Million USD | 99.43% |
| 2008 FY | 6.98 Million USD | 85.67% |
| 2007 FY | 3.76 Million USD | 3.75% |
| 2006 FY | 3.62 Million USD | 0.0% |
| 2001 Q3 | 15.17 Million USD | 0.0% |
| 2001 FY | 77.26 Million USD | 0.0% |
| 2001 Q4 | 22.67 Million USD | 49.37% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bionano Genomics, Inc. | 9.56 Million USD | -427.389% |
| Prenetics Global Limited | 8.82 Million USD | -471.355% |
| Star Equity Holdings, Inc. | 11.92 Million USD | -323.025% |
| CareDx, Inc | 178.32 Million USD | 71.709% |
| Exact Sciences Corporation | 1.84 Billion USD | 97.266% |
| Exagen Inc. | 29.45 Million USD | -71.272% |
| Inotiv, Inc. | 165.44 Million USD | 69.506% |
| Guardant Health, Inc. | 336.89 Million USD | 85.025% |
| Biodesix, Inc. | 36.07 Million USD | -39.84% |
| BioNexus Gene Lab Corp. | 1.32 Million USD | -3694.665% |
| Precipio, Inc. | 6.01 Million USD | -738.318% |
| iSpecimen Inc. | 5.1 Million USD | -887.683% |
| Natera, Inc. | 492.74 Million USD | 89.761% |
| Aspira Women's Health Inc. | 5.26 Million USD | -858.761% |
| 23andMe Holding Co. | 99.37 Million USD | 49.234% |
| Castle Biosciences, Inc. | 174.8 Million USD | 71.139% |
| Personalis, Inc. | 18.2 Million USD | -177.076% |
| Aclaris Therapeutics, Inc. | 13.16 Million USD | -283.126% |
| Applied DNA Sciences, Inc. | 5.53 Million USD | -811.731% |
| OpGen, Inc. | -90.69 Thousand USD | 55726.613% |
| T2 Biosystems, Inc. | -8.17 Million USD | 717.503% |
| Myriad Genetics, Inc. | 476.4 Million USD | 89.41% |
| ICON Public Limited Company | 1.81 Billion USD | 97.219% |
| NeoGenomics, Inc. | 244.6 Million USD | 79.375% |
| Star Equity Holdings, Inc. | 11.92 Million USD | -323.025% |
| IDEXX Laboratories, Inc. | 2.18 Billion USD | 97.696% |
| RadNet, Inc. | 93 Million USD | 45.753% |
| MDxHealth SA | 43.92 Million USD | -14.844% |
| Psychemedics Corporation | 8.41 Million USD | -499.667% |
| Illumina, Inc. | 2.74 Billion USD | 98.161% |
| Check-Cap Ltd. | -212 Thousand USD | 23897.17% |
| Twist Bioscience Corporation | 133.34 Million USD | 62.167% |
| DarioHealth Corp. | 5.98 Million USD | -743.082% |
| Fulgent Genetics, Inc. | 104.45 Million USD | 51.702% |
| Sera Prognostics, Inc. | 96 Thousand USD | -52452.083% |
| ENDRA Life Sciences Inc. | -275.45 Thousand USD | 18415.417% |
| OPKO Health, Inc. | 318.12 Million USD | 84.142% |
| Medpace Holdings, Inc. | 524.5 Million USD | 90.381% |
| Neogen Corporation | 463.9 Million USD | 89.125% |
| Intelligent Bio Solutions Inc. | 1.42 Million USD | -3438.796% |
| Prenetics Global Limited | 8.82 Million USD | -471.355% |
| Mainz Biomed B.V. | 509.65 Thousand USD | -9798.775% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -6273.048% |
| Trinity Biotech plc | 19.45 Million USD | -159.383% |
| Neuronetics, Inc. | 51.7 Million USD | 2.427% |
| Sotera Health Company | 577.15 Million USD | 91.259% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -6273.048% |